Selected article for: "HCoV host and human protein"

Author: Yadi Zhou; Yuan Hou; Jiayu Shen; Yin Huang; William Martin; Feixiong Cheng
Title: Network-based Drug Repurposing for Human Coronavirus
  • Document date: 2020_2_5
  • ID: b4mdiont_53
    Snippet: Integration of drug-target networks, HCoV-host interactions, HCoV-induced transcriptome in human cell lines, and human protein-protein interactome network are essential for such identification. Based on comprehensive evaluation, we prioritized 16 putative repurposable drugs ( Figure 5 ) and 3 putative drug combinations (Figure 6 ) for the potential treatment of HCoVs, including 2019-nCoV. However, all network-predicted repurposable drugs and drug.....
    Document: Integration of drug-target networks, HCoV-host interactions, HCoV-induced transcriptome in human cell lines, and human protein-protein interactome network are essential for such identification. Based on comprehensive evaluation, we prioritized 16 putative repurposable drugs ( Figure 5 ) and 3 putative drug combinations (Figure 6 ) for the potential treatment of HCoVs, including 2019-nCoV. However, all network-predicted repurposable drugs and drug combinations must be validated in preclinical models and randomized clinical trials before being used in patients.

    Search related documents:
    Co phrase search for related documents
    • cell line and comprehensive evaluation: 1
    • cell line and drug combination: 1, 2, 3, 4
    • cell line and drug target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • cell line and drug target network: 1, 2
    • cell line and hcov host: 1, 2
    • cell line and HCoV induced transcriptome: 1
    • cell line and human cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • cell line and human protein protein: 1, 2, 3, 4, 5
    • cell line and network predict: 1
    • cell line and potential treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • clinical trial and comprehensive evaluation: 1, 2, 3
    • clinical trial and drug combination: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • clinical trial and drug target: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • clinical trial and hcov host: 1
    • clinical trial and human cell line: 1, 2
    • clinical trial and human protein protein: 1
    • clinical trial and potential treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • comprehensive evaluation and drug target: 1
    • comprehensive evaluation and network predict: 1, 2